BR112021021092A2 - Composições e métodos úteis na promoção de produção de leite - Google Patents

Composições e métodos úteis na promoção de produção de leite

Info

Publication number
BR112021021092A2
BR112021021092A2 BR112021021092A BR112021021092A BR112021021092A2 BR 112021021092 A2 BR112021021092 A2 BR 112021021092A2 BR 112021021092 A BR112021021092 A BR 112021021092A BR 112021021092 A BR112021021092 A BR 112021021092A BR 112021021092 A2 BR112021021092 A2 BR 112021021092A2
Authority
BR
Brazil
Prior art keywords
notch4
milk production
agent
compositions
promoting milk
Prior art date
Application number
BR112021021092A
Other languages
English (en)
Other versions
BR112021021092A8 (pt
Inventor
Hinck Lindsay
Chatterjee Sharmila
Cazares Oscar
Chen Min
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112021021092A8 publication Critical patent/BR112021021092A8/pt
Publication of BR112021021092A2 publication Critical patent/BR112021021092A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS ÚTEIS NA PROMOÇÃO DE PRODUÇÃO DE LEITE. Trata-se de métodos, agentes e composições para promover a produção de leite em um mamífero são fornecidos. Agentes úteis para promover a produção de leite podem incluir um agente que inibe a atividade de NOTCH4. O agente pode inibir a atividade de NOTCH4 ligando-se a ROBO2 e/ou ligando-se a NOTCH4. O agente pode inibir NOTCH4 competindo com ROBO1 pela ligação ao ROBO2, tornando ROBO1 disponível para inibir a atividade de NOTCH4. O agente pode ser um domínio extracelular ROBO1 solúvel ou um anticorpo anti-NOTCH4 que inibe a atividade NOTCH4. O agente pode ser um construto de RNAi que inibe a expressão de NOTCH4 ou um construto de RNAi que inibe a expressão de ROBO2. Também são fornecidos aqui mamíferos transgênicos geneticamente modificados para a expressão de um domínio extracelular ROBO1 solúvel; inibição da expressão de ROBO2; e/ou inibição da expressão de NOTCH4. Métodos para promover a produção de leite em tais mamíferos transgênicos por administração de um ou mais dos agentes divulgados no presente documento também são fornecidos.
BR112021021092A 2019-04-23 2020-04-22 Composições e métodos úteis na promoção de produção de leite BR112021021092A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837590P 2019-04-23 2019-04-23
PCT/US2020/029386 WO2020219592A1 (en) 2019-04-23 2020-04-22 Compositions and methods useful in promoting milk production

Publications (2)

Publication Number Publication Date
BR112021021092A8 BR112021021092A8 (pt) 2021-12-14
BR112021021092A2 true BR112021021092A2 (pt) 2023-02-28

Family

ID=72921278

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021092A BR112021021092A2 (pt) 2019-04-23 2020-04-22 Composições e métodos úteis na promoção de produção de leite

Country Status (8)

Country Link
US (1) US20200339676A1 (pt)
EP (1) EP3959231A4 (pt)
JP (1) JP2022530033A (pt)
CN (1) CN114401982A (pt)
AU (1) AU2020262256A1 (pt)
BR (1) BR112021021092A2 (pt)
CA (1) CA3136663A1 (pt)
WO (1) WO2020219592A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780009A (en) * 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
AU2003264177A1 (en) * 2002-09-25 2004-04-19 Garvan Institute Of Medical Research Method for inducing mammary epithelial cell differentiation
EP1744162B1 (en) * 2004-03-31 2010-08-04 Hiroyuki Aburatani Cancer diagnosis and treatment using anti-robo1 antibody
US8217000B2 (en) * 2006-05-26 2012-07-10 Cara Therapeutics, Inc. Method for elevating prolactin in mammals
AU2007279205B2 (en) * 2006-07-28 2013-09-26 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US20120192298A1 (en) * 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
FR2958936A1 (fr) * 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
MX351313B (es) * 2012-01-05 2017-10-10 Boston Medical Ct Corp Señalización de slit-robo para diagnosis y tratamiento de enfermedad del riñón.
GB201416832D0 (en) * 2014-09-24 2014-11-05 Glaxosmithkline Plc Methods of treatment
TWI691511B (zh) * 2015-04-16 2020-04-21 日商衛材R&D企管股份有限公司 抗人類Ｎｏｔｃｈ４抗體
AU2018279705A1 (en) * 2017-06-09 2019-11-14 Boston Medical Center Corporation Anti-ROBO2 antibodies, compositions, methods and uses thereof

Also Published As

Publication number Publication date
BR112021021092A8 (pt) 2021-12-14
CN114401982A (zh) 2022-04-26
WO2020219592A1 (en) 2020-10-29
AU2020262256A1 (en) 2021-12-16
CA3136663A1 (en) 2020-10-29
EP3959231A1 (en) 2022-03-02
EP3959231A4 (en) 2023-01-25
US20200339676A1 (en) 2020-10-29
JP2022530033A (ja) 2022-06-27

Similar Documents

Publication Publication Date Title
Baker et al. Distribution and Ca2+ signalling of fibroblast‐like (PDGFRα+) cells in the murine gastric fundus
Erpenbeck et al. Inhibition of platelet GPIbα and promotion of melanoma metastasis
Neidhart et al. Inhibition of spermidine/spermine N1‐acetyltransferase activity: a new therapeutic concept in rheumatoid arthritis
BR112019001247A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo isolado ou fragmento de ligação ao antígeno do mesmo, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para produzir o anticorpo ou fragmento de ligação ao antígeno, composição, e, método de inibição da ativação do complemento da via alternativa em um mamífero.
BRPI0211953B8 (pt) anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
UY33144A (es) Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
Unger-Torroledo et al. Lethal toxin of Clostridium sordellii is associated with fatal equine atypical myopathy
BR112013031485A8 (pt) Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112022021690A2 (pt) Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
BR112019023820A2 (pt) moduladores duplos de receptor de farnesoide x e epóxido hidrolas solúvel
BR112016006649A2 (pt) biscoito macio com glicose de liberação lenta
BR112018008839A8 (pt) métodos e composições para o tratamento da amiloidose
Hempel et al. Binding of Plasmodium falciparum to CD36 can be shielded by the glycocalyx
BR112021021176A2 (pt) Proteína de fusão, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema de complemento de um indivíduo, célula, e, animal não humano geneticamente modificado
CO2020015377A2 (es) Moduladores de la expresión de apol1
BR112018074946A2 (pt) produto lácteo fermentado com um teor reduzido de lactose
Ghoshal et al. Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells
BR112021021092A2 (pt) Composições e métodos úteis na promoção de produção de leite
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t
CL2017000578A1 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia
BR112022012522A2 (pt) Proteínas de ligação de tgf-beta-rii
BR112015020178A2 (pt) composição com propriedades de inflamação reduzidas para pele biológica e método de redução da inflamação do tecido biológico
Salmenkari et al. Local corticosterone production and angiotensin-I converting enzyme shedding in a mouse model of intestinal inflammation
Packham et al. In vivo evidence for platelet-induced physiological angiogenesis by a COX driven mechanism